Name | Role | Date | Shares | Price | Value |
---|---|---|---|---|---|
Kevin M. Brennan | SVP FINANCE AND ACCOUNTING | 2025-01-02 | 1,803 | $0.98 | $1.77kSell |
Christopher James Frankenfield | Chief Financial Officer | 2025-01-02 | 6,954 | $0.98 | $6.84kSell |
Gilead Sciences Inc | 10% Owner | 2024-12-18 | 1,759,978 | $1.04 | $1.83MBuy |
Name | Hold | Shares | Value | Type |
---|---|---|---|---|
Gilead Sciences Inc | 17.59% | 9,105,451 | $7.55M | Insider |
Gilead Sciences Inc | 17.59% | 9,105,451 | $7.55M | Institution |
Yekaterina Chudnovsky | 13.52% | 7,000,000 | $5.80M | Insider |
Bain Capital Life Sciences Investors LLC | 8.82% | 4,566,817 | $3.79M | Institution |
Sv7 Impact Medicine Fund LP | 6.23% | 3,227,264 | $2.68M | Insider |
Rock Springs Capital Management LP | 5.80% | 3,003,259 | $2.49M | Institution |
Bain Capital Life Sciences Investors LLC | 5.42% | 2,805,413 | $2.33M | Insider |
Atlas Venture Fund XI LP | 5.32% | 2,754,109 | $2.28M | Insider |
James E. Flynn | 4.42% | 2,287,944 | $1.90M | Insider |
Merck Co Inc | 2.87% | 1,483,758 | $1.23M | Institution |